• Caris Life Sciences outlined 32 retrospective, real-world studies slated for presentation at the 2026 ASCO Annual Meeting in Chicago on May 29–June 2, including one rapid oral session on MSH3 loss-of-function alterations in patients treated with immune checkpoint blockade across cancer types.
• One Caris-led analysis links genetic ancestry to ultraviolet-related mutational patterns in melanoma, positioning the signal as a potential way to refine immunotherapy response assessment beyond standard mutation-based approaches.
• A separate Caris-led study identifies ESR1 amplification in breast cancer as a distinct genomic subtype tied to poorer outcomes and reduced benefit from CDK4/6 inhibitor therapy, a finding that could influence patient stratification in a major commercial treatment class.
• Additional presentations span immuno-oncology, tumor microenvironment profiling, and treatment response or resistance across tumor types including breast, colorectal, lung, endometrial, and renal cell carcinoma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief on May 22, 2026, and is solely responsible for the information contained therein.